EYENOVIA INC (EYEN)

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 41 full-time employees. The company went IPO on 2018-01-25. The firm is developing the Optejet delivery system both for use in combination with its own drug-device therapeutics and for out-licensing for use in combination with therapeutics for additional indications. Its product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, a well-understood ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. MicroPine program involves the development of a micro-formulation of atropine ophthalmic solution for reduction of myopia progression in children. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation). Its fixed combination product candidate has been developed to facilitate efficient pupil dilation.

Company Info

EYENOVIA INC

295 Madison Ave Ste 2400

New York City NEW YORK 10017

P: 18137669539

CEO: Tsontcho Ianchulev

Employees: 41

Website: https://eyenovia.com/